-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vaccine-induced immune thrombocytopenia and thrombosis formation (Vitt) is coronavirus 2 ChAdOx1nCoV-19 adenoviral vector vaccine-related syndromes emerging with one kind of severe acute respiratory syndrome
.
There is a lack of data on clinical features and prognostic criteria of this disease
Immune Thrombosis
Recently, a research article was published in the top medical journal NEJM.
Researchers conducted a prospective cohort study involving suspected VITT patients who were in a British hospital from March 22 to June 6, 2021
.
Researchers use anonymous spreadsheets to collect data and achieve a clear or possible VITT based on pre-specified criteria
Among the 294 patients evaluated, the researchers identified 170 confirmed and 50 possible VITT cases
.
All patients received the first dose of ChAdOx1nCoV-19 vaccine and appeared 5 to 48 days after vaccination (median 14 days)
The overall mortality rate was 22%, the death rate of patients with cerebral venous sinus thrombosis increased by 2.
7 times (95% confidence interval [CI] from 1.
4 to 5.
2), and the baseline platelet count increased by 1.
7 times for every 50% decrease (95% CI was 1.
3 To 2.
3), for every 10,000 fibrinogen equivalent units increase in baseline D-dimer level, a factor of 1.
2 (95% CI 1.
0 to 1.
3), and a factor of 1.
7 (95% CI 1.
0 to 1.
3) for every 50% decrease in baseline fibrinogen level CI is 1.
1 to 2.
5)
.
Multivariate analysis determined that the baseline platelet count and the presence of intracranial hemorrhage were independently associated with death; in patients with platelet counts below 30,000 per cubic millimetre and intracranial hemorrhage, the observed mortality rate was 73%
It can be seen that among patients with reduced platelet counts and intracranial hemorrhage, the mortality associated with VITT is the highest
.
Treatment is still uncertain, but identifying prognostic markers may help guide effective treatment
Among patients with low platelet counts and intracranial hemorrhage, VITT-related mortality is the highest
